"Pfizer's Weight Loss Drug Ambitions Hinge on Upcoming Data"

Pfizer is aiming to enter the weight loss drug market with its experimental obesity pill, danuglipron, and upcoming data from phase two trials will be crucial in determining its competitiveness against dominant players Eli Lilly and Novo Nordisk. Investors are eagerly awaiting the trial results, hoping to see similar levels of weight loss as Eli Lilly's once-daily pill. Pfizer sees a major opportunity in the weight loss drug segment and aims to capture a significant portion of the market with an oral treatment. The success of Pfizer's data could help boost its share prices and provide relief from the decline caused by the drop in demand for its Covid products.